<DOC>
	<DOCNO>NCT01767701</DOCNO>
	<brief_summary>The purpose study determine whether raltegravir effective prevent progression relapse remit multiple sclerosis determine gadolinium- enhanced MRI .</brief_summary>
	<brief_title>Raltegravir ( Isentress ) Pilot Study Relapsing Multiple Sclerosis</brief_title>
	<detailed_description>There accumulate research evidence Human Endogenous Retrovirus ( HERV ) herpes virus ( particular Epstein-Barr Virus ) involve pathogenesis multiple sclerosis . People active MS high level HERVs people either without MS neurological condition . It show HERVs may produce neurotoxic proteins/antigens associate MS activity disease progression . This first clinical trial investigate hypothesis antiretroviral drug raltegravir may suppress HERV activity ameliorate progression relapse remit MS. Raltegravir integrase inhibitor block retroviral replication . A recent experimental study suggest raltegravir may also active herpes virus . Eligible participant ( see Inclusion/Exclusion Criteria ) observe 3 month monthly brain Gadolinium enhance MRIs blood/urine/saliva sampling ( baseline ) . Then treat raltegravir ( one 400mg pill take twice day ) 3 month . During treatment period participant continue monthly MRIs blood/saliva/urine sample . Participants monthly clinical neurological examination complete questionnaire assess response treatment . Participants screen study visit The Royal London Hospital , Whitechapel . Monthly MRIs perform Institute Neurology Queens Square , London .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Patients 1855 year age . Diagnosis MS , accord revise McDonald Criteria 2010 . EDSS score 06.0 inclusive . Documented least one relapse within past 12 month least one Gdenhanced lesion brain MRI detect within 3 month prior screen date Gdenhanced lesion screen MRI ( MRI use meet screen criterion ) . Female patient childbearing potential expect appropriate contraception ( hormonal barrier method birth control ; abstinence ) time consent 6 week treatment discontinuation . ( repeated administration gadolinium MRI recommend pregnancy ) . NOTE : Subjects consider child bear potential surgically sterile ( undergone hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal . Females childbearing potential must negative urine pregnancy test prior every MRI scan/ within 7 day prior register protocol therapy . Must give write informed consent authorize release use protect health information , require local law . Able willing undergo blood , saliva urine sample regular interval define protocol . Able willing receive Gadolinium enhance MRI 's regular interval define protocol . Able comply study requirement . Pregnant breastfeed unwilling use contraception . Treatment immunosuppressive , immunomodulatory experimental treatment within last 6 month enrolment study , exclude pulse intravenous oral steroid treatment MS relapse . No pulsed intravenous oral steroid 30 day precede baseline assessment . Patients present medical disorder deem severe unstable CI poorly control diabetes arterial hypertension , severe cardiac insufficiency , unstable ischemic heart disease , abnormal liver function test ( &gt; 2.5 time ULN ) abnormal complete blood count ( particular leukopenia , define lymphocyte count &lt; 500 , neutrophil &lt; 1.5 platelet count &lt; 100 , thrombocytopenia &lt; 1.5 LLN ) , medical condition , opinion chief investigator , would pose additional risk patient . Presence human immunodeficiency virus antibody . Patients receive proton pump inhibitor ( e.g . omeprazole/esomeprazole ) Patients active hepatitis B or/and C liver function test &gt; 2.5 time ULN Exposure investigational drug within 30 day enrolment study . Prior history malignancy unless exception grant Chief Investigator . History uncontrolled drug alcohol abuse within 6 month prior enrolment study . Patients treat Rifampicin past four week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>raltegravir</keyword>
	<keyword>MS</keyword>
	<keyword>RRMS</keyword>
	<keyword>Charcot Project</keyword>
</DOC>